Elucidating and Confirming the Substrate and Cofactor Binding Site of RetSat and Identifying the Optimal Cofactor for Retinol Saturase – A Computational Insight

Authors

  • Virangi Tharika Hewage Center for Scientific Computing and Advanced Drug Discovery, University of Sri Jayewardenepura and Department of Chemistry, University of Sri Jayewardenepura, Sri Lanka
  • Ranga Srinath Jayakody Center for Scientific Computing and Advanced Drug Discovery, University of Sri Jayewardenepura and Department of Chemistry, University of Sri Jayewardenepura, Sri Lanka
  • Anura Jayasooriya Department of Basic Veterinary Sciences, University of Peradeniya, Sri Lanka
  • Tharindu Senapathi Department of Chemistry, University of Sri Jayewardenepura, Sri Lanka
  • Krishna Govendar Department of Chemical Sciences, University of Johannesburg, South Africa

DOI:

https://doi.org/10.47852/bonviewMEDIN42023586

Keywords:

retinol saturase, NADH docking in RetSat, Retinol-ATRA conversion inhibition, RetSat 3D atomic structure, RetSat inhibitors for cancer therapy

Abstract

Retinol saturase (RetSat) is an enzyme that inhibits the conversion of all-trans-retinol to all-trans-retinoic acid (ATRA), which is crucial for protecting cells against malignancy. Despite its significance, no effective inhibitors targeting RetSat currently exist, and limited knowledge about its structure, cofactor, and substrate binding has hindered inhibitor design. In this study, we utilized computational techniques to reconstruct and validate the 3D atomic structure of RetSat, identifying its cofactor and substrate binding sites. NADH was determined to be the optimal cofactor and successfully docked into its binding site, followed by docking of retinol into the substrate-specific site. Analysis of the equilibrated complexes revealed key amino acids involved in cofactor and substrate binding, enabling the identification of potential catalytic residues. This study provides validated insights into RetSat’s structure and interactions, offering a foundation for designing RetSat inhibitors as potential anticancer agents and advancing the understanding of its role in cancer biology, thus paving the way for targeted therapeutic strategies.

 

Received: 10 June 2024 | Revised: 10 October 2024 | Accepted: 22 January 2025

 

Conflicts of Interest

The authors declare that they have no conflicts of interest to this work.

 

Data Availability Statement

The data that support this work are available upon reasonable request to the corresponding author.

 

Author Contribution Statement

Virangi Tharika Hewage: Software, Validation, Investigation, Data curation, Writing – original draft, Visualization. Ranga Srinath Jayakody: Conceptualization, Methodology, Validation, Formal analysis, Resources, Data curation, Writing – review & editing, Supervision, Project administration, Funding acquisition. Anura Jayasooriya: Formal analysis, Resources, Data curation, Writing - review & editing, Visualization, Supervision. Tharindu Senapathi: Software, Formal analysis, Resources, Data curation, Writing – review & editing, Visualization, Supervision. Krishna Govendar: Software, Formal analysis, Resources, Data curation, Writing – review & editing, Visualization, Supervision.


Downloads

Published

2025-02-05

Issue

Section

Research Articles

How to Cite

Elucidating and Confirming the Substrate and Cofactor Binding Site of RetSat and Identifying the Optimal Cofactor for Retinol Saturase – A Computational Insight. (2025). Medinformatics. https://doi.org/10.47852/bonviewMEDIN42023586

Funding data